Literature DB >> 10320830

The tissue renin-angiotensin system in human pancreas.

M Tahmasebi1, J R Puddefoot, E R Inwang, G P Vinson.   

Abstract

Evidence exists for the presence of a discrete tissue renin-angiotensin system (RAS) in mouse and rat pancreas that is thought largely to be associated with the vasculature. To investigate this in the human pancreas, and to establish whether the cellular sites of RAS components include the islets of Langerhans, we used immunocytochemistry to localise the expression of angiotensin II (AT1) receptors and (pro)renin, and non-isotopic in situ hybridisation to localise transcription of the (pro)renin gene. Identification of cell types in the islets of Langerhans was achieved using antibodies to glucagon and insulin. The results show the presence of the AT1 receptor and (pro)renin both in the beta cells of the islets of Langerhans, and in endothelial cells of the pancreatic vasculature. Transcription of (pro)renin mRNA, however, was confined to connective tissue surrounding the blood vessels and in reticular fibres within the islets. These findings are similar to those obtained in other tissues, and suggest that renin may be released from its sites of synthesis and taken up by possible cellular sites of action. The results presented here suggest that a tissue RAS may be present in human pancreas and that it may directly affect beta cell function as well as pancreatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10320830     DOI: 10.1677/joe.0.1610317

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  42 in total

1.  Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets.

Authors:  T Lau; P-O Carlsson; P S Leung
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

Review 2.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Curr Opin Pharmacol       Date:  2007-02-15       Impact factor: 5.547

Review 3.  Possible contribution of (pro)renin receptor to development of gestational diabetes mellitus.

Authors:  Kanako Bokuda; Atsuhiro Ichihara
Journal:  World J Diabetes       Date:  2014-12-15

Review 4.  The physiology of a local renin-angiotensin system in the pancreas.

Authors:  Po Sing Leung
Journal:  J Physiol       Date:  2007-01-11       Impact factor: 5.182

Review 5.  The renin angiotensin system and the metabolic syndrome.

Authors:  Annette D de Kloet; Eric G Krause; Stephen C Woods
Journal:  Physiol Behav       Date:  2010-04-08

6.  ACE2 deficiency reduces β-cell mass and impairs β-cell proliferation in obese C57BL/6 mice.

Authors:  Robin Shoemaker; Frederique Yiannikouris; Sean Thatcher; Lisa Cassis
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-08-04       Impact factor: 4.310

7.  Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.

Authors:  Y Nakai; H Isayama; H Ijichi; T Sasaki; N Sasahira; K Hirano; H Kogure; K Kawakubo; H Yagioka; Y Yashima; S Mizuno; K Yamamoto; T Arizumi; O Togawa; S Matsubara; T Tsujino; K Tateishi; M Tada; M Omata; K Koike
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

8.  Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma.

Authors:  S T Glenn; C A Jones; S Sexton; C M LeVea; S M Caraker; G Hajduczok; K W Gross
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

Review 9.  Pancreatic Islet Responses to Metabolic Trauma.

Authors:  Susan J Burke; Michael D Karlstad; J Jason Collier
Journal:  Shock       Date:  2016-09       Impact factor: 3.454

Review 10.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.